Enric Rubio-Contreras

Mr. Enric Rubio-Contreras

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Enric Rubio-ContrerasEnric Rubio-Contreras
Enric Rubio-Contreras
Nora CapellaNora Capella
Nora Capella
AMAlbert Martínez-Pinteño
Albert Martínez-Pinteño
DODavid Olivares-Berjaga
David Olivares-Berjaga
CMConstanza Morén
Constanza Morén
Schizophrenia (SCZ) is a complex psychiatric disorder with positive, negative, and cognitive symptoms that cause long-term functional impairment. Despite available treatments, limitations in addressing cognitive and negative symptoms, medication side effects, and poor adherence highlight the need for novel biomarkers to support precision medicine. Hair has emerged as a promising, non-invasive biological matrix for biomarker research. Hair analysis has been explored to detect trace elements, abused drugs, antipsychotics, cortisol, neurotransmitters, and to assess gene expression, with results often consistent with blood, urine, and post-mortem tissues. Its advantages include ease of sampling and the ability to provide long-term information, while limitations involve individual variability and methodological inconsistencies. This review summarizes current evidence on hair-based biomarkers in SCZ, critically evaluating their potential and challenges. By integrating molecular, metabolic, and genetic findings, we highlight the value of hair as a complementary tool for advancing biomarker discovery and personalized approaches in SCZ.

16 September 2026 in Geriatrics
Verified
Journal Article
Open access
PDF file
CMConstanza Morén
Constanza Morén
APAlonso Pérez-Toribio
Alonso Pérez-Toribio
Enric Rubio-ContrerasEnric Rubio-Contreras
Enric Rubio-Contreras
PÁPatricia Álvaro
Patricia Álvaro
Antonio RosaAntonio Rosa
Antonio Rosa
SPSara Pedregosa-Fauste
Sara Pedregosa-Fauste
Background/Objectives: Schizophrenia is a chronic psychiatric disorder traditionally associated with early adulthood; however, an increasing number of individuals are now reaching older age, highlighting the need to better understand the aging process in this population. Emerging evidence suggests that schizophrenia may be associated with accelerated aging, characterized by an earlier onset of age-related conditions and increased vulnerability to physical and cognitive decline. Methods: We provide an integrative overview of aging in schizophrenia, focusing on biological mechanisms, clinical manifestations, and psychosocial dimensions. Results: Key biological processes, including oxidative stress, mitochondrial dysfunction, chronic immune activation, and dysregulation of stress-response systems, are discussed as potential contributors to accelerated aging. Clinically, older individuals with schizophrenia present a high burden of cardiometabolic comorbidities, persistent cognitive impairment, and increased functional dependency, often compounded by the complexity of pharmacological management in this age group. In addition, psychosocial factors such as social isolation, stigma, and caregiver burden play a critical role in shaping health outcomes and quality of life. Conclusions: Despite growing recognition of these challenges, aging in schizophrenia remains an underexplored area, with significant gaps in longitudinal research and limited focus on older populations. A comprehensive approach that integrates biological, clinical, and psychosocial perspectives is essential to better characterize aging trajectories and to inform more effective and person-centered care strategies in this vulnerable population.

2 October 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
Enric Rubio-ContrerasEnric Rubio-Contreras
Enric Rubio-Contreras
APAlonso Pérez-Toribio
Alonso Pérez-Toribio
PÁPatricia Álvaro
Patricia Álvaro
ACAna M Cosialls
Ana M Cosialls
CMConstanza Morén
Constanza Morén
Schizophrenia (SCZ) remains one of the most disabling psychiatric disorders, in large part because current antipsychotics (APs) inadequately address negative symptoms and cognitive deficits. Converging evidence implicates a set of interconnected mechanisms, NMDAR hypofunction, oxidative stress, and a possible low-grade neuroimmune activation, that converge on parvalbumin-positive GABAergic interneuron dysfunction, the likely substrate of these refractory symptom domains. N-Acetylcysteine (NAC) is an adjunctive candidate because it may act on several of these pathways: it replenishes glutathione (GSH), restores redox balance, and modulates glutamatergic transmission, while its immunomodulatory effects remain poorly characterized in SCZ. This comprehensive review synthesizes evidence from preclinical models and clinical trials, showing that NAC produces replicated but modest benefits for negative symptoms and cognitive function, with inconsistent effects on positive symptoms. Notably, null findings in clinical-high-risk and treatment-resistant populations, together with a single exploratory subgroup analysis in early psychosis in which a peripheral redox index (erythrocyte glutathione peroxidase activity) was associated with positive-symptom response, raise the hypothesis that NAC efficacy may depend on a pre-existing, measurable antioxidant deficit. Adequately powered, biomarker-enriched trials that stratify patients by redox status are therefore needed to determine whether NAC is an effective targeted therapy for a mechanistically defined SCZ subgroup. Such trials would resolve whether the modest effect sizes observed in unselected populations reflect true but limited efficacy or dilution by enrolment of redox-normal patients unlikely to benefit.